LWAC
NBIX icon

Laurel Wealth Advisors (California)’s Neurocrine Biosciences NBIX Stock Holding History

Laurel Wealth Advisors (California)’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		$205K Sell
1,719
-209
-11% -$24.5K 0.02% 632
2022
Q3 		$205K Sell
1,928
-166
-8% -$16.8K 0.02% 609
2022
Q2 		$204K Sell
2,094
-702
-25% -$64.8K 0.02% 637
2022
Q1 		$262K Sell
2,796
-64
-2% -$5.42K 0.02% 633
2021
Q4 		$244K Buy
+2,860
New +$263K 0.02% 690

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Laurel Wealth Advisors (California)'s NBIX Position: Q4 2022 in Review

Laurel Wealth Advisors (California) reduced its Neurocrine Biosciences (NBIX) stake by 11% in Q4 2022, selling an estimated $24.5K and leaving 1,719 shares worth $205K. The position accounts for 0.02% of the portfolio, ranked #632.

Laurel Wealth Advisors (California) first reported a position in NBIX in Q4 2021 and has held it in 5 quarters since. The position peaked at $262K in Q1 2022. 529 funds tracked by Wall St. Rank hold NBIX as of Q4 2022.

  • Laurel Wealth Advisors (California) held 1,719 shares of Neurocrine Biosciences worth $205K as of Q4 2022.
  • Laurel Wealth Advisors (California) sold 209 Neurocrine Biosciences shares in Q4 2022, an estimated $24.5K.
  • Neurocrine Biosciences made up 0.02% of Laurel Wealth Advisors (California)'s portfolio in Q4 2022, its #632 holding.
  • Laurel Wealth Advisors (California) first reported a position in Neurocrine Biosciences in Q4 2021 and has held it in 5 quarters since.
  • Laurel Wealth Advisors (California)'s Neurocrine Biosciences position peaked at $262K in Q1 2022.
  • 529 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2022.

Based on Laurel Wealth Advisors (California)'s 13F filing for Q4 2022, filed 14 Feb 2023.